Evidence map›Paper›PMID 27453223›Full record

ArticleChinese medical journal2016

Routine Hemostasis and Hemogram Parameters: Valuable Assessments for Coagulation Disorder and Chemotherapy in Cancer Patients.

Ying-Wei Zhu, Tong-Bao Feng, Xian-Ju Zhou, Xue-Li Hu, Jie Ding, Wen-Yu Zhu, Dan-Ping Qian, Yi-Wu Sun

Open access · goldAbstract read
In one paragraph

Article in Chinese medical journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Ying-Wei ZhuDepartment of Oncology, Changzhou Second People's Hospital, The Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu 213164, China.
Tong-Bao FengOncology Institute, Changzhou Second People's Hospital, The Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu 213164, China.
Xian-Ju ZhouNeurologic Disease Research Laboratory, Changzhou Second People's Hospital, The Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu 213164, China.
Xue-Li HuDepartment of Oncology, Changzhou Second People's Hospital, The Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu 213164, China.
Jie DingDepartment of Oncology, Changzhou Second People's Hospital, The Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu 213164, China.
Wen-Yu ZhuDepartment of Oncology, Changzhou Second People's Hospital, The Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu 213164, China.
Dan-Ping QianDepartment of Oncology, Changzhou Second People's Hospital, The Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu 213164, China.
Yi-Wu SunDepartment of Hematology, Changzhou Second People's Hospital, The Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu 213164, China.
Nanjing Medical University · CNChangzhou No.2 People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clotting system abnormalities are the common complication in cancer patients. The aim of this retrospective study was to evaluate the coagulation state, clinical features, and treatment in cancer patients by routine tests.

methodsA total of 2328 patients with different types of cancer were classified as the positive group (n = 1419, including 53 patients with thrombosis) and the negative group (n = 909) based on D-dimer (DD) value. Of the 2328 cases, 354 were admitted for chemotherapy. Hemostasis test and complete blood count (CBC) were performed during treatment or following-up.

resultsThis study showed that the hypercoagulable state was affected not only by clinical staging (P < 0.0001) but also by metastasis site (P < 0.0001 for bone vs. lung). Compared to negative DD group, the higher fibrinogen level, the extended activated partial thromboplastin time, and prothrombin time interacted markedly with disease clinical stage (P < 0.05) in the positive group. Between positive DD groups with and without thrombus, the significantly statistic difference in white blood cell (WBC) and DD (P < 0.05) rather than in red blood cell (RBC) and platelet count was observed. However, the higher DD level was not correlated with WBC, RBC, and platelet count in the positive DD group. Furthermore, the hypercoagulable plasma profile in cancer patients was moderated 2-3 weeks after chemotherapy (P < 0.05 for first six cycles).

conclusionsThe routine hemostatic parameters and CBC are valuable to assessment for thrombosis and chemotherapy even for disease prognosis.

Indexed as

AdolescentAdultAgedAged, 80 and overBlood Coagulation DisordersFemaleHemostasisHumansMaleMiddle AgedNeoplasmsRetrospective StudiesThrombosisYoung Adult

Identifiers

PMID27453223
PMCPMC4976562
OpenAlexW2489937020

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.